Page last updated: 2024-11-13

pf-429242

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

PF-429242: a subtilisin kexin isozyme-1/site-1 protease inhibitor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID23661637
CHEMBL ID233611
SCHEMBL ID2742702
MeSH IDM0571321

Synonyms (29)

Synonym
CHEMBL233611 ,
pf-429242
bdbm50216181
(r)-n-(2-methoxyphenethyl)-4-((diethylamino)methyl)-n-(pyrrolidin-3-yl)benzamide
AKOS015998619
pf 429242
S6418
(r)-4-((diethylamino)methyl)-n-(2-methoxyphenethyl)-n-(pyrrolidin-3-yl)benzamide
947303-87-9
(r)-4-((diethylamino)methyl)-n-(2-methoxyphenethyl)-n-(pyrrolidin-3-yl)benz amide
benzamide, 4-((diethylamino)methyl)-n-(2-(2-methoxyphenyl)ethyl)-n-(3r)-3-pyrrolidinyl-
49WB3OA7VN ,
(-)-pf-429242
unii-49wb3oa7vn
J-502224
SCHEMBL2742702
pf429242
DTXSID00635376
4-[(diethylamino)methyl]-n-[2-(2-methoxyphenyl)ethyl]-n-[(3r)-pyrrolidin-3-yl]benzamide
4-[(diethylamino)methyl]-n-[2-(2-methoxyphenyl)ethyl]-n-(3r)-3-pyrrolidinylbenzamide
NCGC00387092-02
pf-429242 dihydrochloride
EX-A1409
4-(diethylaminomethyl)-n-[2-(2-methoxyphenyl)ethyl]-n-[(3r)-pyrrolidin-3-yl]benzamide
Q27259314
NCGC00387092-01
NCGC00387092-03
HY-13447
CS-0006904

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cytochrome P450 2D6Homo sapiens (human)Potency13.45040.00108.379861.1304AID1645840
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Coagulation factor XHomo sapiens (human)IC50 (µMol)100.00000.00030.593710.0000AID299747
Urokinase-type plasminogen activatorHomo sapiens (human)IC50 (µMol)50.00000.03703.385910.0000AID299746
Membrane-bound transcription factor site-1 proteaseHomo sapiens (human)IC50 (µMol)0.17000.17000.17000.1700AID299745
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (33)

Processvia Protein(s)Taxonomy
proteolysisCoagulation factor XHomo sapiens (human)
blood coagulationCoagulation factor XHomo sapiens (human)
positive regulation of cell migrationCoagulation factor XHomo sapiens (human)
positive regulation of TOR signalingCoagulation factor XHomo sapiens (human)
positive regulation of cell migrationUrokinase-type plasminogen activatorHomo sapiens (human)
response to hypoxiaUrokinase-type plasminogen activatorHomo sapiens (human)
proteolysisUrokinase-type plasminogen activatorHomo sapiens (human)
chemotaxisUrokinase-type plasminogen activatorHomo sapiens (human)
signal transductionUrokinase-type plasminogen activatorHomo sapiens (human)
blood coagulationUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of signaling receptor activityUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of plasminogen activationUrokinase-type plasminogen activatorHomo sapiens (human)
negative regulation of plasminogen activationUrokinase-type plasminogen activatorHomo sapiens (human)
smooth muscle cell migrationUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of smooth muscle cell migrationUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of cell adhesionUrokinase-type plasminogen activatorHomo sapiens (human)
plasminogen activationUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of cell adhesion mediated by integrinUrokinase-type plasminogen activatorHomo sapiens (human)
urokinase plasminogen activator signaling pathwayUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of cell population proliferationUrokinase-type plasminogen activatorHomo sapiens (human)
fibrinolysisUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of fibrinolysisUrokinase-type plasminogen activatorHomo sapiens (human)
negative regulation of fibrinolysisUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of wound healingUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of smooth muscle cell-matrix adhesionUrokinase-type plasminogen activatorHomo sapiens (human)
proteolysisMembrane-bound transcription factor site-1 proteaseHomo sapiens (human)
lysosome organizationMembrane-bound transcription factor site-1 proteaseHomo sapiens (human)
mitotic G2 DNA damage checkpoint signalingMembrane-bound transcription factor site-1 proteaseHomo sapiens (human)
cholesterol metabolic processMembrane-bound transcription factor site-1 proteaseHomo sapiens (human)
protein processingMembrane-bound transcription factor site-1 proteaseHomo sapiens (human)
endoplasmic reticulum unfolded protein responseMembrane-bound transcription factor site-1 proteaseHomo sapiens (human)
membrane protein intracellular domain proteolysisMembrane-bound transcription factor site-1 proteaseHomo sapiens (human)
response to endoplasmic reticulum stressMembrane-bound transcription factor site-1 proteaseHomo sapiens (human)
ATF6-mediated unfolded protein responseMembrane-bound transcription factor site-1 proteaseHomo sapiens (human)
regulation of cholesterol biosynthetic processMembrane-bound transcription factor site-1 proteaseHomo sapiens (human)
protein maturationMembrane-bound transcription factor site-1 proteaseHomo sapiens (human)
regulation of vesicle-mediated transportMembrane-bound transcription factor site-1 proteaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
serine-type endopeptidase activityCoagulation factor XHomo sapiens (human)
calcium ion bindingCoagulation factor XHomo sapiens (human)
protein bindingCoagulation factor XHomo sapiens (human)
phospholipid bindingCoagulation factor XHomo sapiens (human)
serine-type endopeptidase activityUrokinase-type plasminogen activatorHomo sapiens (human)
protein bindingUrokinase-type plasminogen activatorHomo sapiens (human)
serine-type endopeptidase activityMembrane-bound transcription factor site-1 proteaseHomo sapiens (human)
protein bindingMembrane-bound transcription factor site-1 proteaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (18)

Processvia Protein(s)Taxonomy
extracellular regionCoagulation factor XHomo sapiens (human)
endoplasmic reticulum lumenCoagulation factor XHomo sapiens (human)
Golgi lumenCoagulation factor XHomo sapiens (human)
plasma membraneCoagulation factor XHomo sapiens (human)
external side of plasma membraneCoagulation factor XHomo sapiens (human)
extracellular spaceCoagulation factor XHomo sapiens (human)
extracellular regionUrokinase-type plasminogen activatorHomo sapiens (human)
extracellular spaceUrokinase-type plasminogen activatorHomo sapiens (human)
plasma membraneUrokinase-type plasminogen activatorHomo sapiens (human)
focal adhesionUrokinase-type plasminogen activatorHomo sapiens (human)
external side of plasma membraneUrokinase-type plasminogen activatorHomo sapiens (human)
cell surfaceUrokinase-type plasminogen activatorHomo sapiens (human)
specific granule membraneUrokinase-type plasminogen activatorHomo sapiens (human)
extracellular exosomeUrokinase-type plasminogen activatorHomo sapiens (human)
tertiary granule membraneUrokinase-type plasminogen activatorHomo sapiens (human)
serine protease inhibitor complexUrokinase-type plasminogen activatorHomo sapiens (human)
protein complex involved in cell-matrix adhesionUrokinase-type plasminogen activatorHomo sapiens (human)
serine-type endopeptidase complexUrokinase-type plasminogen activatorHomo sapiens (human)
extracellular spaceUrokinase-type plasminogen activatorHomo sapiens (human)
Golgi membraneMembrane-bound transcription factor site-1 proteaseHomo sapiens (human)
Golgi membraneMembrane-bound transcription factor site-1 proteaseHomo sapiens (human)
endoplasmic reticulum lumenMembrane-bound transcription factor site-1 proteaseHomo sapiens (human)
endoplasmic reticulum membraneMembrane-bound transcription factor site-1 proteaseHomo sapiens (human)
Golgi stackMembrane-bound transcription factor site-1 proteaseHomo sapiens (human)
Golgi apparatusMembrane-bound transcription factor site-1 proteaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (46)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1861755Cytotoxicity against human CFBE41o- cells expressing CFTR P.Phe508del mutant at 10 uM incubated for 48 hrs by MTT assay2022Bioorganic & medicinal chemistry letters, 09-15, Volume: 72Evaluation of aminopyrrolidine amide to improve chloride transport in CFTR-defective cells.
AID1861750Induction of UPR in human CFBE41o- cells expressing CFTR P.Phe508del mutant assessed as upregulation of PERK mRNA expression by RT-PCR analysis2022Bioorganic & medicinal chemistry letters, 09-15, Volume: 72Evaluation of aminopyrrolidine amide to improve chloride transport in CFTR-defective cells.
AID299768Antilipogenic activity in CD1 mouse assessed as inhibition of fatty acid synthetic pathway at 10 mg/kg, ip every 6 hrs for 24 hrs2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Aminopyrrolidineamide inhibitors of site-1 protease.
AID1861748Effect on S1P protein expression in human CFBE41o- cells expressing CFTR P.Phe508del mutant by Western blot analysis2022Bioorganic & medicinal chemistry letters, 09-15, Volume: 72Evaluation of aminopyrrolidine amide to improve chloride transport in CFTR-defective cells.
AID299745Inhibition of human S1P expressed in CHOK1 cells2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Aminopyrrolidineamide inhibitors of site-1 protease.
AID1861751Induction of UPR in human CFBE41o- cells expressing CFTR P.Phe508del mutant assessed as upregulation of IRE1 mRNA expression by RT-PCR analysis2022Bioorganic & medicinal chemistry letters, 09-15, Volume: 72Evaluation of aminopyrrolidine amide to improve chloride transport in CFTR-defective cells.
AID1861754Upregulation of BiP protein expression in human CFBE41o- cells expressing CFTR P.Phe508del mutant by Western blot analysis2022Bioorganic & medicinal chemistry letters, 09-15, Volume: 72Evaluation of aminopyrrolidine amide to improve chloride transport in CFTR-defective cells.
AID299755Inhibition of cholesterol synthesis in rat liver2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Aminopyrrolidineamide inhibitors of site-1 protease.
AID299746Inhibition of urokinase2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Aminopyrrolidineamide inhibitors of site-1 protease.
AID299753Reduction of fatty acid synthase expression in mouse liver2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Aminopyrrolidineamide inhibitors of site-1 protease.
AID1861752Upregulation of cleaved form of ATF6 protein expression in human CFBE41o- cells expressing CFTR P.Phe508del mutant by Western blot analysis2022Bioorganic & medicinal chemistry letters, 09-15, Volume: 72Evaluation of aminopyrrolidine amide to improve chloride transport in CFTR-defective cells.
AID299754Inhibition of cholesterol synthesis in HepG2 cells2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Aminopyrrolidineamide inhibitors of site-1 protease.
AID299748Inhibition of proteolytic processing of SREBP in HepG2 cells at 10 uM2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Aminopyrrolidineamide inhibitors of site-1 protease.
AID1861753Upregulation of ATF6 protein expression in human CFBE41o- cells expressing CFTR P.Phe508del mutant by Western blot analysis2022Bioorganic & medicinal chemistry letters, 09-15, Volume: 72Evaluation of aminopyrrolidine amide to improve chloride transport in CFTR-defective cells.
AID1861758Restoration of CFTR chloride channel activity in human CFBE41o- cells expressing CFTR P.Phe508del mutant assessed as increase in transcription of CFTR P.Phe508del mutant mRNA expression by RT-qPCR analysis2022Bioorganic & medicinal chemistry letters, 09-15, Volume: 72Evaluation of aminopyrrolidine amide to improve chloride transport in CFTR-defective cells.
AID299749Inhibition of nuclear translocation of SREBP in HepG2 cells at 10 uM2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Aminopyrrolidineamide inhibitors of site-1 protease.
AID299760Plasma clearance in rat2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Aminopyrrolidineamide inhibitors of site-1 protease.
AID1861759Restoration of CFTR chloride channel activity in Chinese hamster BHK cells expressing 3HA-epitope tagged CFTR P.Phe508del mutant assessed as increase in exportation of mutant CFTR to membrane by measuring mature CFTR by immunoblot analysis2022Bioorganic & medicinal chemistry letters, 09-15, Volume: 72Evaluation of aminopyrrolidine amide to improve chloride transport in CFTR-defective cells.
AID299757Inhibition of fatty acid synthesis in rat liver at 10 uM2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Aminopyrrolidineamide inhibitors of site-1 protease.
AID299763Antilipogenic activity in CD1 mouse assessed as reduction of HMG-CoA synthase gene expression at 30 mg/kg, ip every 6 hrs for 24 hrs2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Aminopyrrolidineamide inhibitors of site-1 protease.
AID299751Reduction of HMG-CoA synthase expression in mouse liver2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Aminopyrrolidineamide inhibitors of site-1 protease.
AID299766Antilipogenic activity in CD1 mouse assessed as inhibition of cholesterol synthetic pathway at 10 mg/kg, ip every 6 hrs for 24 hrs2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Aminopyrrolidineamide inhibitors of site-1 protease.
AID299759Inhibition of LDL receptor-mediated LDL internalization in HepG2 cells2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Aminopyrrolidineamide inhibitors of site-1 protease.
AID299758Inhibition of LDL receptor gene expression in HepG2 cells2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Aminopyrrolidineamide inhibitors of site-1 protease.
AID1861747Effect on S1P protein expression in human CFBE41o- cells expressing wild type CFTR by Western blot analysis2022Bioorganic & medicinal chemistry letters, 09-15, Volume: 72Evaluation of aminopyrrolidine amide to improve chloride transport in CFTR-defective cells.
AID1861757Restoration of CFTR chloride channel activity in human CFBE41o- cells expressing wild type CFTR assessed as increase in channel function at 10 uM at -80 mV holding potential incubated for 48 hrs by whole cell patch clamp assay2022Bioorganic & medicinal chemistry letters, 09-15, Volume: 72Evaluation of aminopyrrolidine amide to improve chloride transport in CFTR-defective cells.
AID299761Oral bioavailability in rat2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Aminopyrrolidineamide inhibitors of site-1 protease.
AID299752Reduction of fatty acid synthase expression in mouse hepatocytes2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Aminopyrrolidineamide inhibitors of site-1 protease.
AID1861756Restoration of CFTR chloride channel activity in human CFBE41o- cells expressing CFTR P.Phe508del mutant assessed as increase in channel function by measuring Cl- current at 10 uM at -80 mV holding potential incubated for 48 hrs by whole cell patch clamp 2022Bioorganic & medicinal chemistry letters, 09-15, Volume: 72Evaluation of aminopyrrolidine amide to improve chloride transport in CFTR-defective cells.
AID299756Inhibition of fatty acid synthesis in in HepG2 cells at 10 uM2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Aminopyrrolidineamide inhibitors of site-1 protease.
AID299750Reduction of HMG-CoA synthase expression in mouse hepatocytes2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Aminopyrrolidineamide inhibitors of site-1 protease.
AID299767Antilipogenic activity in CD1 mouse assessed as inhibition of cholesterol synthetic pathway at 30 mg/kg, ip every 6 hrs for 24 hrs2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Aminopyrrolidineamide inhibitors of site-1 protease.
AID299770Antilipogenic activity in CD1 mouse assessed as reduction of LDL receptor gene expression at 30 mg/kg, ip every 6 hrs for 24 hrs2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Aminopyrrolidineamide inhibitors of site-1 protease.
AID1861749Induction of UPR in human CFBE41o- cells expressing CFTR P.Phe508del mutant assessed as upregulation of XBP1 mRNA expression by RT-PCR analysis2022Bioorganic & medicinal chemistry letters, 09-15, Volume: 72Evaluation of aminopyrrolidine amide to improve chloride transport in CFTR-defective cells.
AID299769Antilipogenic activity in CD1 mouse assessed as inhibition of fatty acid synthetic pathway at 30 mg/kg, ip every 6 hrs for 24 hrs2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Aminopyrrolidineamide inhibitors of site-1 protease.
AID299765Antilipogenic activity in CD1 mouse assessed as reduction of fatty acid synthase gene expression at 30 mg/kg, ip every 6 hrs for 24 hrs2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Aminopyrrolidineamide inhibitors of site-1 protease.
AID299764Antilipogenic activity in CD1 mouse assessed as reduction of fatty acid synthase gene expression at 10 mg/kg, ip every 6 hrs for 24 hrs2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Aminopyrrolidineamide inhibitors of site-1 protease.
AID299762Antilipogenic activity in CD1 mouse assessed as reduction of HMG-CoA synthase gene expression at 10 mg/kg, ip every 6 hrs for 24 hrs2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Aminopyrrolidineamide inhibitors of site-1 protease.
AID299747Inhibition of factor 10a2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Aminopyrrolidineamide inhibitors of site-1 protease.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (27)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (3.70)29.6817
2010's16 (59.26)24.3611
2020's10 (37.04)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.37

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.37 (24.57)
Research Supply Index3.33 (2.92)
Research Growth Index6.21 (4.65)
Search Engine Demand Index32.99 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (29.37)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (7.41%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other25 (92.59%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]